Respiratory Syncytial Virus Prophylaxis

This publication has 11 references indexed in Scilit:

• Surveillance of Clinical Isolates of Respiratory Syncytial Virus for Palivizumab (Synagis)–Resistant Mutants
  The Journal of Infectious Diseases, 2004
• Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized with Respiratory Syncytial Virus Infection
  The Pediatric Infectious Disease Journal, 2004
• Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model
  Antimicrobial Agents and Chemotherapy, 2004
• Compliance with prophylaxis for respiratory syncytial virus infection in a home setting
  The Pediatric Infectious Disease Journal, 2004
• Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
  Pediatrics, 2003
• Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
  The Journal of Pediatrics, 2003
• Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry
  Pediatric Pulmonology, 2003
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
  Pediatrics, 1998
• Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis
  Pediatrics, 1997
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children
  New England Journal of Medicine, 1993